| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10158572 | Pulmonary Pharmacology & Therapeutics | 2018 | 30 Pages |
Abstract
Therefore, these preliminary data referring to our single-centre observational study corroborate, in a real-life environment, the efficacy of mepolizumab for treatment of patients with exacerbation-prone, corticosteroid-refractory, severe eosinophilic asthma.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Corrado Pelaia, Maria Teresa Busceti, Sabina Solinas, Rosa Terracciano, Girolamo Pelaia,